Insulet

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. 

CEO
Ashley A. McEvoy
CEOAshley A. McEvoy
Employees
3,900
Employees3,900
Headquarters
Acton, Massachusetts
HeadquartersActon, Massachusetts
Founded
2000
Founded2000
Employees
3,900
Employees3,900

PODD Key Statistics

Market cap
19.90B
Market cap19.90B
Price-Earnings ratio
80.71
Price-Earnings ratio80.71
Dividend yield
Dividend yield
Average volume
650.52K
Average volume650.52K
High today
$284.25
High today$284.25
Low today
$275.10
Low today$275.10
Open price
$277.04
Open price$277.04
Volume
781.78K
Volume781.78K
52 Week high
$354.88
52 Week high$354.88
52 Week low
$230.05
52 Week low$230.05

Stock Snapshot

With a market cap of 19.9B, Insulet(PODD) trades at $282.89. The stock has a price-to-earnings ratio of 80.71.

On 2026-01-14, Insulet(PODD) stock moved within a range of $275.10 to $284.25. With shares now at $282.89, the stock is trading +2.8% above its intraday low and -0.5% below the session's peak.

Trading activity shows a volume of 781.78K, compared to an average daily volume of 650.52K.

Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $230.05.

Over the past 52 weeks, Insulet(PODD) stock has traded between a high of $354.88 and a low of $230.05.

PODD News

TipRanks 3d
Barclays downgrades Insulet to Underweight on intensifying competition

Barclays analyst Matt Miksic downgraded Insulet (PODD) to Underweight from Equal Weight with a price target of $274, down from $316. As new competition approach...

Analyst ratings

90%

of 30 ratings
Buy
90%
Hold
6.7%
Sell
3.3%

People also own

Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .